Cemiplimab vs Sintilimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03088540 · Phase 3 · completed

This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.

Next expected readout: December 2026 · NCT06623656 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)

Result source: NCT03088540

Sintilimab

Marketed by Innovent Biologics and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03607539 · Phase 3 · completed

This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.

Next expected readout: November 2026 · NCT05429463 (registry estimate)

Reported efficacy

Overall Survival (Through database cutoff date of 31-July-2020 (up to approximately 35 months)): Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). (met)

Result source: NCT03150875

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemiplimabSintilimab
PFS, median6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
8.9 vs 5+3.9 vs placebon 266NCT03607539
2 other results
OS, median21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
11.8 vs 8.3vs Docetaxeln 145NCT03150875
ORR43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
51.9% vs 29.8%+22.1 vs placebon 266NCT03607539
2 other results
  • 44.7% vs 35.4% n 179 · Phase 3 · secondary NCT03629925
  • 25.5% vs 2.2% n 145 · Phase 3 · secondary NCT03150875
Duration of response, median16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
6.0 vs 5.1+1 vs placebon 80NCT03629925
1 other result

PFS, median

Cemiplimab
6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
Sintilimab
8.9 vs 5+3.9 vs placebon 266NCT03607539
2 other results

OS, median

Cemiplimab
21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
Sintilimab
11.8 vs 8.3vs Docetaxeln 145NCT03150875

ORR

Cemiplimab
43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
Sintilimab
51.9% vs 29.8%+22.1 vs placebon 266NCT03607539
2 other results
  • 44.7% vs 35.4% n 179 · Phase 3 · secondary NCT03629925
  • 25.5% vs 2.2% n 145 · Phase 3 · secondary NCT03150875

Duration of response, median

Cemiplimab
16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
Sintilimab
6.0 vs 5.1+1 vs placebon 80NCT03629925
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cemiplimab: 4 of 4 rows · Sintilimab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabSintilimab
Dropout rate
79%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
90.7%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
90.1%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneb
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
n/a: no completion milestone
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
0.3%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
0%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
0.3%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—b
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
—
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
36.8%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
27.1%Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
35.2%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
30.4%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
28.2%b
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
38.9%
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
50.3%
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
a
anaemia 19.7%
decreased appetite 13.8%
fatigue 13.5%
NCT03088540 · Phase 3
show 10 more results
anaemia 31.8%
alopecia 22.4%
diarrhoea 18.8%
NCT03088540 · Phase 3 · combination
anaemia 48.1% (placebo 39.9%)
neutropenia 28.7% (placebo 12.4%)
alopecia 27.8% (placebo 43.8%)
NCT03409614 · Phase 3 · combination
anaemia 33.9% (placebo 39.9%)
nausea 28.4% (placebo 16.3%)
fatigue 21.1% (placebo 8.5%)
NCT03409614 · Phase 3 · combination
anaemia 44.2% (placebo 39.9%)
alopecia 37.5% (placebo 43.8%)
nausea 25.3% (placebo 16.3%)
NCT03409614 · Phase 3 · combination
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
b
anaemia 74.1% (placebo 78.6%)
neutrophil count decreased 71.1% (placebo 62.6%)
white blood cell count decreased 67.7% (placebo 64.1%)
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
anaemia 33.3%
decreased appetite 23.6%
pyrexia 21.5%
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
anaemia 93.3% (placebo 90.4%)
white blood cell count decreased 88.8% (placebo 86%)
neutrophil count decreased 83.2% (placebo 82%)
NCT03629925 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cemiplimab

EORTC QLQ-C30 GHS 4.92 vs 0.45 Chemotherapy score @ 3wk
absolute change · score
Cycle 2, Day 1 (C2D1)
NCT03088540 · Phase 3
show 2 more results
2.13 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
1.58 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 7.23 vs 1.25 Chemotherapy score @ 6wk
absolute change · score
C3D1
NCT03088540 · Phase 3
show 3 more results
4.65 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
2.75 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
0.96 vs 2.8 placebo score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.13 vs 2.43 Chemotherapy score @ 9wk
absolute change · score
C4D1
NCT03088540 · Phase 3
show 3 more results
6.22 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
3 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
1.92 vs 4.09 placebo score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.27 vs 1.88 Chemotherapy score @ 12wk
absolute change · score
C5D1
NCT03088540 · Phase 3
show 3 more results
3.31 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
4.72 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
3.35 vs 2.28 placebo score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 9.64 vs 3 Chemotherapy score @ 15wk
absolute change · score
C6D1
NCT03088540 · Phase 3
show 3 more results
5.63 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.38 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.42 vs 2.89 placebo score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.19 vs 2.55 Chemotherapy score @ 24wk
absolute change · score
C9D1
NCT03088540 · Phase 3
show 3 more results
6.87 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
1.8 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
3.65 vs 2.02 placebo score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 11.11 vs -4.17 Chemotherapy score @ 33wk
absolute change · score
C12D1
NCT03088540 · Phase 3
show 3 more results
4.44 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
9.15 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
2.37 vs 3.54 placebo score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.88 vs 5.36 Chemotherapy score @ 42wk
absolute change · score
C15D1
NCT03088540 · Phase 3
show 3 more results
7.35 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
9.4 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
6.23 vs 6.61 placebo score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.1 vs -3.03 Chemotherapy score @ 51wk
absolute change · score
C18D1
NCT03088540 · Phase 3
show 3 more results
6.73 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
14.44 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
5.28 vs 10.09 placebo score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 13.42 vs -1.19 Chemotherapy score @ 60wk
absolute change · score
C21D1
NCT03088540 · Phase 3
show 3 more results
11.36 vs 0 Chemotherapy score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
15.71 vs 0 Chemotherapy score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
6.07 vs 18.59 placebo score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.76 vs 1.19 Chemotherapy score @ 69wk
absolute change · score
C24D1
NCT03088540 · Phase 3
show 3 more results
8.33 vs -11.11 Chemotherapy score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
14.29 vs -11.11 Chemotherapy score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
5.05 vs 10.83 placebo score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 12.5 vs -3.33 Chemotherapy score @ 78wk
absolute change · score
C27D1
NCT03088540 · Phase 3
show 3 more results
8.89 vs -22.22 Chemotherapy score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination
19.05 vs -22.22 Chemotherapy score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination
5.27 vs 8.33 placebo score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination

+ 36 further endpoints in the CSV export.

Sintilimab

Disease Control 86.8% (n=266) vs 75.6% (n=131) placebo
responder rate · % of participants
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
86% (n=179) vs 80.3% (n=178) placebo
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Time to Response 1.51 vs 2.63 placebo months
time to event · months
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
1.41 vs 1.41 placebo months
NCT03629925 · Phase 3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Sintilimab's landscape